Motivators for Alzheimer’s disease clinical trial participation

  • Shoshana H. Bardach
  • Sarah D. Holmes
  • Gregory A. Jicha
Short Communication

Abstract

Background

Alzheimer’s disease (AD) research progress is impeded due to participant recruitment challenges. This study seeks to better understand, from the perspective of individuals engaged in clinical trials (CTs), research motivations.

Methods

Participants, or their caregivers, from AD treatment and prevention CTs were surveyed about research motivators.

Results

The 87 respondents had a mean age of 72.2, were predominantly Caucasian, 55.2% were male, and 56.3% had cognitive impairment. An overwhelming majority rated the potential to help themselves or a loved one and the potential to help others in the future as important motivators. Relatively few respondents were motivated by free healthcare, monetary rewards, or to make others happy.

Conclusions

Recruitment efforts should focus on the potential benefit for the individual, their loved ones, and others in the future rather than free healthcare or monetary rewards.

Keywords

Clinical trials Motivation Recruitment 

References

  1. 1.
    Alzheimer’s Association (2015) 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11:332–384CrossRefGoogle Scholar
  2. 2.
    Vellas B et al (2012) Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology. J Nutr Health Aging 16:339–345CrossRefPubMedGoogle Scholar
  3. 3.
    Knebl JA, Patki D (2010) Recruitment of subjects into clinical trials for Alzheimer disease. J Am Osteopath Assoc 110(9 Suppl 8):S43–S49PubMedGoogle Scholar
  4. 4.
    McDonald AM et al (2006) What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 7:1–8CrossRefGoogle Scholar
  5. 5.
    Watson JL et al (2014) Obstacles and opportunities in Alzheimer’s clinical trial recruitment. Health Aff (Millwood) 33:574–579CrossRefGoogle Scholar
  6. 6.
    Grill JD et al (2013) Risk disclosure and preclinical Alzheimer’s disease clinical trial enrollment. Alzheimers Dement 9:356.e1–359.e1CrossRefGoogle Scholar
  7. 7.
    Treweek S et al (2013) Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. BMJ Open 3:e002360CrossRefGoogle Scholar
  8. 8.
    Grill JD, Karlawish J (2010) Addressing the challenges to successful recruitment and retention in Alzheimer’s disease clinical trials. Alzheimers Res Ther 2:34CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cooper C, Ketley D, Livingston G (2014) Systematic review and meta-analysis to estimate potential recruitment to dementia intervention studies. Int J Geriatr Psychiatry 29:515–525CrossRefPubMedGoogle Scholar
  10. 10.
    Williams, MM et al. (2010) Barriers and facilitators of African American participation in Alzheimer disease biomarker research. Alzheimer Dis Assoc Disord 24(Suppl):S24–S29.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Shoshana H. Bardach
    • 1
    • 2
  • Sarah D. Holmes
    • 3
  • Gregory A. Jicha
    • 2
    • 4
  1. 1.Graduate Center for Gerontology, College of Public HealthUniversity of KentuckyLexingtonUSA
  2. 2.Sanders-Brown Center on AgingUniversity of KentuckyLexingtonUSA
  3. 3.University of MarylandBaltimoreUSA
  4. 4.Department of NeurologyUniversity of KentuckyLexingtonUSA

Personalised recommendations